BIOMAT Database Logo BIOMAT Database Logo

Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. 1993

A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
University Department of Medicine, Ninewells Hospital and Medical School, Dundee.

OBJECTIVE To determine whether plasma concentrations of tissue plasminogen activator antigen, von Willebrand factor antigen, and prostacyclin stimulating factor and plasminogen activator inhibitor activity show circadian variation in men with ischaemic heart disease. METHODS Blood samples were obtained every four hours for 24 hours from 10 men with ischaemic heart disease. The men were ambulant from 08:10 until 00:00 when they went to bed and they remained in bed until 08:00 the following morning. METHODS Ten men with positive diagnostic exercise tolerance tests with no significant past history, who were not regularly taking any medical treatment except for glyceryl trinitrate. RESULTS There was significant circadian variation in plasminogen activator inhibitor activity (p = 0.001) (peak value 04:00 and trough value 20:00), but not in plasma concentrations of tissue plasminogen activator antigen, von Willebrand factor, or prostacyclin stimulating factor. CONCLUSIONS Men with ischaemic heart disease showed a significant circadian variation in fibrinolysis. The combination of peak values of plasminogen activator inhibitor activity and failure of plasma concentrations of tissue plasminogen activator antigen to increase in the early morning must predispose to thrombosis at this time. The circadian variation in fibrinolysis may contribute to the increased incidence of myocardial infarction in the morning.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D001685 Biological Factors Endogenously synthesized compounds that influence biological processes not otherwise classified under ENZYMES; HORMONES or HORMONE ANTAGONISTS. Biologic Factors,Biological Factor,Factor, Biologic,Factor, Biological,Factors, Biological,Biologic Factor,Factors, Biologic
D014841 von Willebrand Factor A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. Factor VIII-Related Antigen,Factor VIIIR-Ag,Factor VIIIR-RCo,Plasma Factor VIII Complex,Ristocetin Cofactor,Ristocetin-Willebrand Factor,von Willebrand Protein,Factor VIII Related Antigen,Factor VIIIR Ag,Factor VIIIR RCo,Ristocetin Willebrand Factor

Related Publications

A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
September 1993, Clinical rheumatology,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
January 1995, Scandinavian journal of rheumatology,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
August 1995, Thrombosis and haemostasis,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.
May 1991, Annals of the rheumatic diseases,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.
June 1992, Clinical rheumatology,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
May 2008, Diabetes care,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Genetic influences on fibrinogen, tissue plasminogen activator-antigen and von Willebrand factor in males and females.
March 2006, Thrombosis and haemostasis,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
[A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease].
June 1993, Zhonghua xin xue guan bing za zhi,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke.
August 2002, Atherosclerosis,
A B Bridges, and M McLaren, and N A Scott, and T H Pringle, and G P McNeill, and J J Belch
von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
September 1992, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!